Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

about

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

Item

http://www.wikidata.org/entity/Q52806531

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@en

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@nl

type

Item

label

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@en

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@nl

prefLabel

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@en

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@nl

P1476

Clinical and MRI remission in ...... esults of the ABILITY-1 trial.

@en

P2093

Aileen L Pangan

http://www.w3.org/2001/XMLSchema#string

Jaclyn K Anderson

http://www.w3.org/2001/XMLSchema#string

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

Maja Hojnik

http://www.w3.org/2001/XMLSchema#string

Robert G Lambert

http://www.w3.org/2001/XMLSchema#string

Su Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Secukinumab for ankylosing spondylitis and psoriatic arthritis

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

P2888

s13075-018-1556-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-018-1556-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Désirée van der Heijde

Walter P Maksymowych

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101775739

http://www.w3.org/2001/XMLSchema#string

P698

29587851

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5870399

http://www.w3.org/2001/XMLSchema#string